between stromal cell-derived factor (SDF)-1 and CXC chemokine receptor (CXCR)4. Ischemic injury disrupts the SDF-1-CXCR4 interaction and releases BM PCs into the peripheral circulation, where the mobilized cells are recruited to the injured tissue and contribute to vessel growth. BM PCs can also be mobilized by the pharmacological CXCR4 antagonist AMD3100, but the other components of the SDF-1-CXCR4 signaling pathway are largely unknown. c-kit, a membrane-bound tyrosine kinase and the receptor for stem cell factor, has also been shown to play a critical role in BM PC mobilization and ischemic tissue repair.
the injured tissue and contribute to vessel growth. 11, 12 BM PCs can also be mobilized by the pharmacological CXCR4 antagonist AMD3100, [13] [14] [15] but the downstream components of the SDF-1-CXCR4 signaling pathway are largely unknown.
Like CXCR4, c-kit is expressed predominantly in BM PCs, and the ligand for c-kit, stem cell factor (SCF), is constitutively produced by BM endothelial cells and fibroblasts. 16 c-kit is a class III receptor tyrosine kinase, and administration of a c-kit-neutralizing antibody (ACK2) to wild-type (WT) mice released BM cells to the peripheral circulation and enhanced the engraftment of intravenously injected BM cells. 17 On the other hand, PC mobilization is markedly blunted in c-kit W/W-V mutant mice, which are defective in c-kit kinase activity but have normal levels of c-kit expression and SCF binding at the cell surface. 18 -21 Furthermore, the kinetics of BM PC mobilization induced by the c-kitneutralizing antibody and by the antagonism of CXCR4 with AMD3100 were similar. Collectively, these findings suggest that SCF-c-kit signaling participates in BM PC mobilization and trafficking, 22, 23 but whether the SDF-1-CXCR4 and SCF-c-kit pathways interact is unknown.
Here, we show that SDF-1-CXCR4 signaling is mediated, at least in part, by c-kit phosphorylation. AMD3100 administration failed to mobilize BM PCs in c-kit W/W-V mice or in mice transplanted with BM cells that expressed a constitutively active c-kit mutant, and BM levels of phosphorylated (phospho)-c-kit declined after both AMD3100 administration and induction of a CXCR4 knockout mutation. In cells adhering to plates coated with vascular cell adhesion molecule (VCAM)-1, SDF-1 and SCF increased phospho-c-kit levels, and AMD3100 treatment suppressed SDF-1-induced, but not SCF-induced, c-kit phosphorylation. Furthermore, pretreatment of cells with a selective Src inhibitor blocked both c-kit phosphorylation and the interaction between c-kit and phospho-Src. Collectively, these results suggest that the regulation of BM PC trafficking by SDF-1 and CXCR4 is linked to Src-mediated c-kit phosphorylation.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice c-kit w/w-v (WBB6F1/J-Kit W /Kit W-V /J) and WT mice (male, 10 to 12 weeks old) were purchased from The Jackson Laboratory. CXCR4 fl/fl and CXCR4 BAC -GFP transgenic mice were provided by Dr Richard J. Miller (Northwestern University). 24, 25 The Mx1cre ϩ CXCR4 fl/fl mice were bred by mating CXCR4 fl/fl and Mx1-cre (The Jackson Laboratory) mice, and CXCR4 gene deletion was induced with 3 intraperitoneal injections of 250 g of poly(I)poly(C) (GE Healthcare) administered at 2-day intervals. 26 All surgical procedures were approved by the Institutional Animal Care and Use Committee of Northwestern University.
Isolation of BM and PB MNCs
BM and PB MNCs were isolated as described previously 26 and as detailed in the Online Methods section.
PC Colony-Forming Assay
PB and BM MNCs were isolated, and the PC colony-forming assay was performed in 35-mm dishes with a semisolid methylcellulose medium containing SCF and other recombinant cytokines (MethoCult GF M3434, StemCell Technologies, Canada), as directed by the protocol of the manufacturer; 2ϫ10 5 PB MNCs and 2ϫ10 4 BM MNCs were seeded in each dish, and colonies were counted 12 days later. To ensure that c-kit w/w-v PC levels would not be underestimated, Flt3-ligand (R&D Systems; final concentration, 100 ng/mL) was added to the medium to compensate for cells that may not respond well to SCF.
BM Clearance/Repopulation Assay
AMD3100 (5 mg/kg) was subcutaneously injected into WT and c-kit w/w-v mice to mobilize PCs from the BM. Two hours later, 27 40ϫ10 6 BM MNCs that had been isolated from eGFP-transgenic mice (C57BL/6-Tg[ACTB-eGFP]; The Jackson Laboratory) were injected into the tail vein and allowed to repopulate the BM for 3 hours 28 ; then, BM MNCs were isolated from the recipients, and eGFP expression was evaluated by flow cytometry.
Flow Cytometry
Flow cytometric analyses of gene expression in isolated BM and PB MNCs were performed as described previously. 26 
Transplantation of Retrovirally Transduced c-kit WT and c-kit D816V BM MNCs
MIG-HyKIT WT and MIG-HyKIT D816V retroviral vectors were generated by cotransfecting 293FT cells with a packaging plasmid, pIK6.1 MCV.ecopac.UTd, and 1 of 2 backbone plasmids: pMSCV-HyKIT WT -IRES-eGFP (pMIG-HyKIT WT ) or pMSCV-HyKIT D816V -IRES-eGFP (pMIG-HyKIT D816V ). 29 Methods for virus generation, BM MNC isolation and ex vivo expansion, viral infection, and BM transplantation are described in the Online Methods section.
Tissue Sectioning and Immunofluorescent Staining
Mice were subcutaneously injected with AMD3100 (5 mg/kg) or PBS and euthanized 30 minutes later. Femurs were harvested, fixed, and immunofluorescently stained as described in the Online Methods section. 
Non-standard Abbreviations and Acronyms

Cell Adhesion Assay
The BM MNC adhesion assay was performed as described previously. 26
Western Blotting and Coimmunoprecipitation
Western blotting and coimmunoprecipitation was performed as described previously, 30, 31 and additional details can be found in the Online Methods section.
Quantitative Real-Time RT-PCR
Real-time RT-PCR was performed via standard techniques, 32 as detailed in the Online Methods section.
Statistics
Data are presented as meansϮSEM. Comparisons between 2 means were assessed for significance with the unpaired Student's t test;
comparisons between 3 or more means were assessed for significance via ANOVA and Bonferroni multiple comparison procedures. Statistical significance was assigned if PϽ0.05.
Results
AMD3100-Induced PC Mobilization Is Impaired in c-kit w/w-v Mice
We initiated our investigation into the potential involvement of c-kit in CXCR4-mediated BM PC trafficking by quantifying the levels of colony forming PCs in the PB and BM of WT mice and mice defective in the kinase activity of c-kit (c-kit w/w-v mice). PB PC levels significantly increased and BM PC levels significantly declined 2 hours after AMD3100 injection in WT mice but not in c-kit w/w-v mice ( Figure 1A and 1B). To determine whether the impaired mobilization observed in c-kit w/w-v mice was limited to specific subpopu- lation(s) of PCs, we developed a short-term, in vivo BM clearance/repopulation assay. WT and c-kit w/w-v mice were treated with or without AMD3100, and then 40ϫ10 6 BM MNCs from enhanced green fluorescent protein (eGFP)transgenic mice were intravenously injected 2 hours later. 14, 27 Three hours after cell injection, 28 MNCs were isolated from the BM, and flow cytometric analysis was performed for eGFP expression, to identify injected cells that had repopulated the BM, and for the expression of CXCR4, c-kit, Lin, and Sca-1. In the absence of AMD3100 treatment, eGFP expression was negligible (Ͻ0.01% of cells) in BM MNCs from both c-kit w/w-v and WT mice. In AMD3100-treated mice, the proportion of BM MNCs that expressed eGFP did not differ significantly between strains ( Figure 1C ) and neither did the proportion of eGFP ϩ MNCs that coexpressed CXCR4 ( Figure 1D ) or Lin ( Figure 1E ), or the proportion of eGFP ϩ Lin Ϫ cells. However, the proportion of eGFP ϩ Lin Ϫ cells that coexpressed CXCR4 (c-kit w/w-v : 16.3%; WT: 30.6%; PϽ0.01), Sca-1 and CXCR4 (c-kit w/w-v : 16.6%; WT: 29.7%; PϽ0.01), or c-kit and CXCR4 (c-kit w/w-v : 5.7%; WT: 17.8%; PϽ0.001) was significantly lower in c-kit w/w-v mice than in WT mice ( Figure 1F ). These significant differences could occur if the c-kit W/W-V mutation impaired the recruitment of PCs to the BM, but expression of the PC chemoattractant SDF-1 was similar in both strains (Online Figure I) . Thus, the c-kit W/W-V mutation appeared to block the mobilization of Lin Ϫ CXCR4 ϩ cells that coexpressed Sca1 or c-kit, and because the Lin Ϫ Sca1 ϩ and Lin Ϫ c-kit ϩ phenotypes are typically associated with PC identity, these observations suggest that a loss of c-kit kinase activity impairs the AMD3100-induced mobilization of CXCR4 ϩ PCs.
AMD3100 Fails to Mobilize PCs That Express a Constitutively Active c-kit Mutant (c-kit D816V )
Because AMD3100-induced BM PC mobilization is impaired in c-kit-kinase defective mice, we investigated whether increasing the level of activated c-kit would enhance AMD3100-induced mobilization. WT BM MNCs were transfected with retroviral vectors coding for eGFP and WT c-kit (c-kit WT ) or eGFP and a constitutively active c-kit mutant (c-kit D816V ) 29, 33 (Figure 2A and 2B) and then transplanted into WT mice after lethally irradiating the endogenous BM. Three weeks later, the numbers of BM MNCs in the 2 recipient strains were similar. Furthermore, the expression of eGFP and of the transgene were driven by the same promoter (CMV), so the high proportion of eGFP ϩ BM and PB MNCs ( Figure 2C ) confirmed that transgene expression persisted for at least 3 weeks after transplantation. The constitutive activation of c-kit in BM MNCs from mice transplanted with c-kit D816V -transduced cells was verified via Western blot (Online Figure II) . On the third week after BM transplantation, the recipient mice were treated with AMD3100 or PBS, and the numbers of eGFP ϩ PCs in the BM and PB were determined 2 hours later. AMD3100 treatment significantly increased the number of eGFP ϩ PB PCs ( Figure 2D) , and significantly decreased the number of eGFP ϩ BM PCs (Figure 2E ), in mice transplanted with MNCs that overexpressed c-kit WT but not in mice transplanted with c-kit D816V -expressing MNCs. Thus, either a deficiency ( Figure 1A and 1B) or the constitutive activation of c-kit kinase activity ( Figure 2D and 2E) impaired AMD3100-induced BM PC mobilization. Collectively, these observations suggest that CXCR4-mediated BM PC mobilization requires a change in the phosphorylation state of c-kit.
SDF-1/CXCR4 Signaling Upregulates c-kit Phosphorylation in BM MNCs In Vitro
Previous reports suggest that c-kit participates in PC mobilization through an ␣4-integrin-mediated mechanism, 19 and that interactions between ␣4-integrin and VCAM-1 support the adhesion and retention of MNCs in the BM. 26 Thus, we performed a series of in vitro experiments to determine whether the phosphorylation state of c-kit is altered by ␣4-integrin-mediated adhesion and CXCR4 signaling. Freshly isolated WT and c-kit w/w-v BM MNCs were applied to VCAM-1-coated or uncoated plates, allowed to adhere for 15 minutes, incubated with or without AMD3100 for another 15 minutes, and then c-kit phosphorylation at tyrosine719 was evaluated via Western blotting. The VCAM-1 coating did not induce c-kit phosphorylation in c-kit w/w-v cells, but phospho-c-kit levels were notably higher in adherent WT cells (ie, cells from VCAM-1-coated plates) than in nonadherent WT cells (ie, cells from uncoated plates) ( Figure 3A ). In adherent WT cells, treatment with an ␣4-integrinblocking antibody ( Figure 3B ) reduced phospho-c-kit levels, whereas treatment with the CXCR4 ligand SDF-1 markedly increased phospho-c-kit levels ( Figure 3C ). Furthermore, both SDF-1 and SCF (ie, c-kit ligand) induced c-kit phosphorylation, but c-kit levels were highest when the cells were incubated with both factors ( Figure 3C ), and AMD3100 treatment suppressed SDF-1-induced, but not SCF-induced, c-kit phosphorylation ( Figure 3D ). Notably, similar results were obtained after treating HEK293 cells that transiently expressed CXCR4 and c-kit with SDF-1, SCF, or AMD3100 alone and in combination ( Figure 3E and 3F), and AMD3100 treatment did not downregulate c-kit phosphorylation in BM MNCs transduced with the constitutively active c-kit D816V mutant ( Figure 3G ). Collectively, these observations suggest that MNC adhesion is associated with an increase in phospho-ckit levels, and that in adherent MNCs, SDF-1 upregulates, and AMD3100 downregulates (in the presence of exogenous SDF-1), c-kit phosphorylation. Thus, AMD3100 appears to induce BM MNC mobilization through a decline in phosphoc-kit levels. Furthermore, SDF-1-and SCF-induced c-kit activation may occur independently and regulate different cellular activities.
Antagonism or Genetic Deletion of CXCR4 Downregulates BM c-kit Phosphorylation In Vivo
To determine whether CXCR4 also regulates BM MNC c-kit phosphorylation in vivo, WT mice were treated with AMD3100 or PBS and euthanized 30 minutes later, and then BM phospho-c-kit levels were evaluated by Western blot; phospho-c-kit levels were distinctly lower in mice administered AMD3100 than in PBS-treated mice ( Figure 4A ). These findings were corroborated by breeding Mx1-cre ϩ mice with CXCR4 fl/fl mice 24 to generate Mx1-cre ϩ CXCR4 fl/fl offspring, which carry an inducible CXCR4 knockout mutation that is triggered by poly(I)-poly(C) injection. 26 Two weeks after the CXCR4 knockout mutation was induced, real-time RT-PCR analyses confirmed that CXCR4 expression had fallen to only Ϸ5% of the levels observed in CXCR4-expressing mice ( Figure 4B) , and BM phospho-c-kit levels had also declined ( Figure 4C and 4D) . These observations were corroborated by administering AMD3100 or PBS to CXCR4 BAC GFP mice, which carry a BAC (bacterial artificial chromosome) coding for GFP expression driven by the human CXCR4 genomic regulatory sequence. 25 The mice were euthanized 30 minutes after treatment, and then sections of the femoral BM ( 
Figure 3. SDF-1/CXCR4 signaling upregulates c-kit phosphorylation in BM MNCs and in HEK293 cells in vitro. A through D, BM
MNCs were isolated from WT and c-kit w/w-v mice and applied to uncoated plates or to plates coated with the stromal protein VCAM-1 to mimic adhesion in the BM. Fifteen minutes later, the levels of phospho-c-kit (P-c-kit) and total c-kit were analyzed by Western blot in WT and c-kit w/w-v cells (A), in WT cells incubated with or without an anti-␣4-integrin antibody (Anti-␣4 Ab) (B), and in WT cells incubated with the indicated combinations of SCF, SDF-1, or AMD3100 (C and D). P-c-kit levels were quantified densitometrically, normalized to the total c-kit level, and expressed as the fold difference from the levels measured in WT cells applied to uncoated plates and incubated without treatment. Values are meansϮSEM (*PϽ0.05, **PϽ0.01, ***PϽ0.001; nϭ6 to 8 per treatment). E and F, HEK293 cells were cotransfected with pMyc-CXCR4 and pMSCV-HyKIT WT -IRES-eGFP plasmids via standard techniques; 24 hours later, the transfected cells were treated with the indicated combinations of SCF, SDF-1, and AMD3100 for 15 minutes, lysed, and then P-c-kit and total c-kit levels were evaluated via Western blot. Representative results from 4 experiments are shown. G, WT BM MNCs were transduced with retroviral vectors coding for WT (c-kit WT ) or constitutively active (c-kit D816V ) c-kit as described for Figure 2 , and then the cells were applied to VCAM-1-coated plates and stimulated with SDF-1 for 15 minutes in the presence or absence of AMD3100, and the levels of P-c-kit and total c-kit were analyzed via Western blot. Values are meansϮSEM (**PϽ0.01; N.S., not significant; nϭ6 per treatment). 4E) were immunofluorescently stained for total c-kit ( Figure  4F ) and phospho-c-kit ( Figure 4G ). The proportion of CXCR4-expressing (ie, GFP ϩ ) cells that coexpressed phospho-c-kit was significantly lower in sections harvested from AMD3100-treated mice than from mice administered PBS ( Figure 4H) . Notably, phospho-c-kit and CXCR4 were coexpressed by the majority of cells located near the endosteum and surrounding the sinusoidal vessels, where high numbers of PCs are typically found. These observations confirm that CXCR4 regulates c-kit phosphorylation in the BM.
We also investigated whether the expression of CXCR4 and c-kit changed in response to BM MNC mobilization. Flow cytometric analysis of BM and PB MNCs isolated from CXCR4 BAC GFP transgenic mice indicated that both CXCR4 (ie, GFP fluorescence) and c-kit were expressed by a much greater proportion of BM MNCs (CXCR4: 93%; c-kit: Ϸ26%) than PB MNCs (CXCR4: Ϸ55%; c-kit: Ϸ0.60%) (Online Figure III, A) . CXCR4 expression was similarly distributed when evaluated by staining cells with a fluorescent anti-CXCR4 antibody (data not shown). Because c-kit expression is Ϸ40-fold more common among BM MNCs than PB MNCs, MNC mobilization should substantially increase the proportion of PB MNCs that express c-kit, unless c-kit expression is altered during mobilization. However, the proportion of PB MNCs that expressed c-kit was unchanged 2 hours after AMD3100 treatment (Online Figure III, B) , whereas the proportion of PB MNCs that expressed GFP (ie, the number of circulating, BM-derived cells) increased from Ϸ60% to Ϸ89%. Thus, AMD3100-induced MNC mobilization is associated with a decline in c-kit expression, as well as c-kit phosphorylation.
SDF-1/CXCR4-Induced c-kit Phosphorylation Is Mediated by Src Kinase
CXCR4 is a G protein-coupled receptor, and previous reports suggest that signaling through G protein-coupled receptors activates the Src family of protein tyrosine kinases (SFKs) 34 ; furthermore, the SDF-1/CXCR4 axis has been shown to activate Lyn, an SFK that is expressed in hematopoietic cells. 35 Thus, we investigated whether Src kinase has a role in SDF-1/CXCR4-induced c-kit phosphorylation.
SDF-1 treatment markedly increased Src phosphorylation at tyrosine 416 (which signals Src activation) in HEK293 cells that transiently expressed CXCR4 and c-kit, and Src phosphorylation was followed by c-kit phosphorylation (Src: Ϸ2 minutes; c-kit: Ϸ10 minutes) ( Figure 5A ). SDF-1 also induced Src and c-kit phosphorylation in freshly isolated mouse BM MNCs adhered to VCAM-1-coated plates, whereas cotreatment with AMD3100 attenuated the SDF-1induced phosphorylation of both proteins ( Figure 5B ), and cotreatment with the selective Src kinase inhibitor SU6656 dose-dependently blocked c-kit phosphorylation ( Figure 5C ). Furthermore, c-kit coimmunoprecipitated with phospho-Src 
Figure 4. Antagonism or genetic deletion of CXCR4 downregulates c-kit phosphorylation in the BM in vivo. A,
WT mice were subcutaneously injected with AMD3100 (5 mg/kg) or PBS; 30 minutes later, phospho-c-kit (P-c-kit) and total c-kit levels were evaluated via Western blot. B through D, Mx1-creCXCR4 fl/fl mice were treated with or without 3 intraperitoneal injections of 250 g poly(I)-poly(C) at 2-day intervals. Two weeks after the last injection, CXCR4 expression in BM MNCs from the untreated (ie, CXCR4 fl/fl ) mice (fl/fl) and from the treated (ie, CXCR4 knockout) mice (⌬/⌬) was assessed via realtime RT -PCR (B) , and the levels of P-ckit in BM lysates were evaluated by Western blot (C), quantified densitometrically, and normalized to the levels of total c-kit (D) (nϭ4). E and F, Bone tissue harvested from CXCR4 BAC -eGFP transgenic mice was evaluated histologically. Sections were stained with hematoxylin/eosin to show the trabecular region of the femurs (Endo, endosteum; M, megakaryocyte; Ob, osteoblast; Sinu, Sinusoidal vessel) (E) or immunofluorescently stained to reveal partial colocalization of c-kit (red) and CXCR4 (green) (F). G and H, CXCR4 BAC -eGFP transgenic mice were treated with AMD3100 (5 mg/kg) or PBS, euthanized 30 minutes later, and bone tissues were harvested and immunofluorescently stained for the presence of P-c-kit (red) (G); then, the proportion of P-c-kit ϩ cells in the total c-kit ϩ cell population was quantified (H). Values are meansϮSEM; nϭ5 mice per group.
( Figure 5D ) in adherent BM MNCs, which suggests that phospho-Src binds to c-kit in vivo, and the levels of c-kitbound phospho-Src increased after SDF-1 treatment ( Figure  5D and 5E); once again, the effects of SDF-1 treatment declined in BM MNCs cotreated with ADM3100 ( Figure 5D ) or SU6656 ( Figure 5E ). Collectively, these observations suggest that SDF-1-induced c-kit phosphorylation requires the activation of Src and, consequently, that SDF-1 and CXCR4 regulate BM PC trafficking through a Src-and c-kit-dependent pathway.
Discussion
The mobilization of PCs from the BM to the peripheral circulation is a crucial step in the response to ischemic injury. Researchers in other laboratories have shown that BM PC retention is largely governed by interactions between SDF-1 and CXCR4 and that the selective CXCR4 antagonist AMD3100 disrupts these interactions, thereby releasing PCs into the peripheral circulation. For these reasons, AMD3100 and other treatments that enhance PC mobilization are currently being investigated for use in cell-based therapeutic approaches designed to promote tissue repair 12, 26, 36 and to treat a number of diseases. 13, 37 Our findings provide the first evidence that SDF-1-CXCR4 binding retains PCs in the BM by transactivating c-kit and that CXCR4 antagonism mobilizes PCs by downregulating c-kit phosphorylation. Furthermore, phospho-c-kit has been shown to activate phosphatidylinositol 3-kinase (PI3K) (through the p85 regulatory subunit), Ras mitogen-activated protein kinase (through growth factor receptor-bound protein 2), and integrins (eg, VLA-4/VCAM-1), which are linked to the regulation of cell adhesion and mobility, 38 and results from other labs suggest that growth factors such as granulocyte colonystimulating factor (G-CSF) mobilize BM PCs by triggering the enzymatic cleavage of membrane-bound SCF-c-kit and SDF-1-CXCR4 complexes. 39, 40 Thus, SDF-1-CXCR4 -c-kit signaling could function as a "final common pathway" of fundamental importance to BM PC retention and mobilization.
Because G-CSF-induced PC mobilization requires an increase in c-kit activation, 9 the decline in c-kit phosphorylation reported here may seem counterintuitive. However, G-CSF-induced mobilization occurs 3 to 5 days after administration and is accompanied by an increase in the number of PCs present in the perivascular niche, 41 whereas AMD3100-induced mobilization occurs within a few hours and, consequently, is unlikely to be preceded by the perivascular accumulation of PCs. Furthermore, the 2 agents appear to mobilize different PC subpopulations, and more PCs are mobilized when G-CSF and AMD3100 administration are combined than when G-CSF is administered alone. [42] [43] [44] Thus, the available evidence suggests that the mechanisms of G-CSF-and AMD3100-induced PC mobilization differ substantially. G-CSF and other slow-acting agents may increase c-kit phosphorylation by upregulating SCF, which (by itself) has only a modest effect on mobilization but potently promotes PC proliferation 45 ; if so, G-CSF-induced mobilization may be delayed until an adequate surplus of PCs is available for release to the PB. 41 Conversely, fast-acting agents, such as AMD3100 or the 4-integrin-blocking antibody, may mobilize PCs directly by reducing c-kit phosphorylation in the perivascular niche. 46 This hypothesis is also supported by recent evidence that PCs can be rapidly mobilized by the administration of a c-kit-neutralizing antibody. 17 Both the loss and the constitutive activation of c-kit kinase activity impaired AMD3100-induced BM PC mobilization. In c-kit kinase-defective mice, BM PC levels were lower than in WT mice, and systemically administered CXCR4 ϩ PCs could not repopulate the BM. These observations suggest that c-kit kinase inactivation blocks the retention of CXCR4 ϩ PCs in the BM and, consequently, that the cells susceptible to AMD3100-induced mobilization are (in effect) already mobilized. In mice transplanted with BM cells that expressed a constitutively active c-kit mutant, AMD3100 treatment did not alter PC levels in the BM or the PB, which suggests that CXCR4mediated BM PC mobilization requires c-kit kinase deactivation. Collectively, these observations indicate that PCs are retained in the BM by the kinase activity of c-kit, and that AMD3100 mobilizes CXCR4 ϩ BM PCs by downregulating c-kit kinase activity.
Our observations also indicate that SDF-1/CXCR4induced c-kit transactivation is mediated by SFKs. CXCR4 is a G protein-coupled receptor, and 2 families of G-protein ␣ subunits (G␣s and G␣I) activate SFKs (c-Src and Hck) by binding directly to the catalytic domain and increasing substrate access to the active site. 34 CXCR4dependent stimulation of SFKs (Lyn) has also been associated with the activation of PI3K. 35 However, SFKs display considerable redundancy both in their activation pathways and in the downstream effectors that mediate their biological function 47 ; therefore, whether the G proteins, PI3K, or other upstream components link the SDF-1/CXCR4 axis to SFK activation and, subsequently, to c-kit phosphorylation and BM PC retention, has yet to be determined.
There are nine known SFKs, several of which, as well as multiple isoforms of the same SFK, are expressed in any given tissue. SU6656 inhibits all SFKs (without directly altering c-kit activity), 48 and the available antibodies are not specific for the phosphorylated forms of individual family members; therefore, we used antibodies against activated SFKs that are found predominantly in the hematopoietic system (ie, Lyn, Hck, and Fgr). Thus, the results reported here cannot identify which specific SFK mediates c-kit activation. We have begun a series of experiments with mice deficient in one or more SFK to characterize the roles of the individual family members.
In conclusion, the results presented here demonstrate that SDF-1/CXCR4 signaling retains PCs in the BM through the Src-mediated activation of c-kit and that CXCR4 antagonism induces PC mobilization by downregulating c-kit phosphorylation. Because BM PCs have an essential role in tissue repair, the mechanism identified by our studies could be an important component of the physiological response to ischemic injury. Furthermore, SDF-1, CXCR4, and c-kit also have a role in normal development and in diseases such as arthritis and cancer 49, 50 ; therefore, the implications of our findings may extend to a wide variety of pathological and developmental processes.
